Biotech stocks took another beating Friday, led by Gilead Sciences as concerns grew about its blockbuster drug Sovaldi. Gilead (GILD) tumbled 4% to close at 68.55, a four-month low. The stock was already hit the previous Friday on word of a congressional inquiry into its high price for Sovaldi, launched in December as a revolutionary treatment for hepatitis C. This Friday, IMS Health prescription data for the week ended March 21
Virtual reality might soon be a reality, its backers say. While most observers greeted with skepticism Facebook’s (FB) surprise announcement Tuesday that it would buy a virtual reality startup for $2.2 billion, others praised Facebook CEO Mark Zuckerberg’s foresight. True, the VR dreams of technologists, futurists and sci-fi writers remain largely unfulfilled. But progress is tantalizing. “We are moving into a period now where we
The go-to source of news for Americans has shifted from newspapers to broadcast television to websites with each successive generation. For millennials, those young consumers often called digital natives, their principal source of news is shaping up to be their smartphones and apps. The app-ification of the news is shaking up the media world, with players new and old trying to attract the next generation of news consumers. So far,